metricas
covid
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Actividad de cuatro fluoroquinolonas frente a cepas de Pseudomonas aeruginosa co...
Journal Information
Vol. 19. Issue 9.
Pages 432-434 (November 2001)
Share
Share
Download PDF
More article options
Vol. 19. Issue 9.
Pages 432-434 (November 2001)
Full text access
Actividad de cuatro fluoroquinolonas frente a cepas de Pseudomonas aeruginosa con diferente patrón de sensibilidad a ceftazidima e imipenem
Visits
6793
Álvaro Pascuala,1
Corresponding author
atomas@cica.es

Correspondencia: Dr. Á. Pascual. Departamento de Microbiología. Facultad de Medicina. Apdo. 914. Sevilla 41080
, Providencia Joyanesa, Luis Martínez-Martíneza, María del Carmen Conejoa, Gonzalo Hernándezb, José Chavesb, Evelio J. Pereaa
a Departamento de Microbiología. Facultad de Medicina. Sevilla
b Departamento de Investigación y Desarrollo. Parke Davis. Madrid
This item has received
Article information
Fundamento

Evaluar la actividad de cuatro fluoroquinolonas (ciprofloxacino, clinafloxacino, norfloxacino y pefloxacino) frente cepas clínicas de Pseudomas aeruginosa con diferentes patrones de sensibilidad a ceftazidima e imipenem

Material y métodos

Se estudiaron 156 cepas de P. aeruginosa aisladas en el Hospital Universitario Virgen Macarena de Sevilla en los años 1998 y 1999. La actividad in vitro de cuatro fluoroquinolonas se determinó mediante microdilución en caldo Mueller Hinton suplementado con cationes siguiendo las recomendaciones del NCCLS

Resultados

Para el total de cepas evaluadas, los valores de concentración mínima inhibitoria (CMI)90 de clinafloxacino (4 mg/l) fueron significativamente inferiores a los de ciprofloxacino (64 mg/l). Para las 76 cepas resistentes a ciprofloxacino, las CMI90 de clinafloxacino y ciprofloxacino fueron de 16 y > 128 mg/l respectivamente. Clinafloxacino fue más activa que ciprofloxacino, norfloxacino y pefloxacino, con independencia del patrón de sensibilidad o resistencia a ceftazidima e imipenem

Conclusión

Clinafloxacino fue más activa in vitro que ciprofloxacino frente a P. aeruginosa

Palabras clave:
P aeruginosa
clinafloxacino
resistencia
Objectives

To evaluate the activity of four fluorquinolones (ciprofloxacin, clinafloxacin, norfloxacin and perfloxacin) against clinical strains of Pseudomonas aeruginosa with different sensitivity patterns to ceftazidime and imipenem

Material and methods

156 strains of isolated P. aeruginosa were studied at the Virgin Macarena University Hospital in Seville during 1998 and 1999. The in vitro activity of four fluorquinolones was determined by microdilution in Mueller Hinton bouillon, supplemented with cations, following the NCCLS guidelines

Results

For all the strains evaluated, the minimum inhibitory concentration values (MIC90) of the clinafloxacin (4 mg/l) were significantly less than those for ciprofloxacin (64 mg/l). In the 76 strains resistant to ciprofloxacin, the clinafloxacin and ciprofloxacin MCI90 were 16 and >128 mg/l respectively. Clinafloxacin was more active than ciprofloxacin, norfloxacin and pefloxacin, independent to the sensitivity pattern or the resistance to ceptazidime and imipenem

Conclusion

Clinafloxacin was more active in vitro than ciprofloxacin against P. aeruginosa

Key words:
P aeruginosa
clinafloxacin
resistance
Full text is only aviable in PDF
Bibliografía
[1.]
R.E.W. Hancock.
Resistance mechanism in Pseudomonas aeruginosa and other nonfermentative Gram-negative bacteria.
Clin Microbiol Dis, 27 (1998), pp. S93-S99
[2.]
E. Cambau, E. Perani, C. Dib, C. Petinon, J. Trias, V. Jarlier.
Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem.
Antimicrob Agents Chemohter, 39 (1995), pp. 2.248-2.252
[3.]
T. Kohler, J.C. Pechere, P. Plesiat.
Bacterial antibiotic efflux systems of medical importance.
Cell Mol Life Sci, 56 (1999), pp. 771-778
[4.]
L. Xian-Zhi, L. Zhang, K. Poole.
Interplay between the MexA-MexB-OprM multidurg efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa.
J Antimicrob Chemother, 45 (2000), pp. 433-436
[5.]
I. Ziha-Zaifi, C. Llanes, T. Köler, J.C. Pechere, P. Plesiat.
In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB OprM.
Antimicrob Agents Chemother, 43 (1999), pp. 287-291
[6.]
A. Lee, W. Mao, M.S. Warren, A. Mistry, K. Hoshino, R. Okumura, et al.
Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance.
J Bacteriol, 182 (2000), pp. 3.142-3.150
[7.]
F.J. Schmitz, A.C. Fluit, D. Milatovic, J. Verhoef, H.P. Heinz, S. Brisse.
In vitro potency of moxifloxacin, clinafloxacin and sitafloxacin against 248 genetically defined clinical isolates of Staphylococcus aureus.
J Antimicrob Chemother, 46 (2000), pp. 109-113
[8.]
A. Pascual, I. López-Hernández, L. Martínez-Martínez, E.J. Perea.
In vitro susceptibilities of multiresistant strains of Acinetobacter baumannii to eight quinolones.
J Antimicrob Chemother, 40 (1997), pp. 140-142
[9.]
J.R. Hernández, L. Martínez-Martínez, A. Pascual, A.I. Suárez, E.J. Perea.
Trends in the susceptibilities of Proteus mirabilis isolates to quinolones.
J Antimicrob Chemother, 45 (2000), pp. 407-408
[10.]
L. Martínez-Martínez, P. Joyanes, A. Pascual, E. Terrero, E.J. Perea.
Activity of eight fluorquinolones against enterococci.
Clin Microbiol Infect, 45 (1997), pp. 407-408
[11.]
L. Martínez-Martínez, A.I. Suárez, M.C. Ortega, E.J. Perea.
Comparative in vitro activities of new quinolones against coryneform bacteria.
Antimicrob Agents Chemother, 38 (1994), pp. 1.439-1.441
[12.]
P. Joyanes, B. Mazza, L. Martínez, G. López-López, A. Pascual.
Actividad de ocho fluoroquinolonas frente a biocapas de Escherichia coli y Pseudomonas aeruginosa sobre sondas urinarias de látex siliconizado.
Enferm Infecc Microbiol Clin, 18 (2000), pp. 27-40
[13.]
O. Lomovskaya, M.S. Warren, A. Lee, J. Galazzo, R. Fronko, M. Lee, et al.
Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy.
Antimicrob Agents Chemother, 45 (2001), pp. 105-116
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos